Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179396 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
A Phase 1 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04179396: Completed Phase 1 study, sponsored by pharmaand.
NCT04179396 is a Phase 1 study that has completed, run by pharmaand. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04179396, a Phase 1 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
Primary Outcome
Cmin of rucaparib and its metabolite. Rucaparib only run-in Cmin includes run-in D6, D7 and Cycle 1 D1. All of these samples were collected following rucaparib monotherapy. Rucaparib and other anticancer agent Combination Cmin includes Cycle 1 (D8, D15, and D22).
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 1 |
What the finished NCT04179396 record still lists
NCT04179396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT04179396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04179396 about?
NCT04179396 is a clinical study titled "Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)". Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
What is the current status of trial NCT04179396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-12-05. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT04179396?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT04179396?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04179396's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI